{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:01:10Z","timestamp":1794024070243,"version":"4.8.0"},"reference-count":210,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Merck Serono S.p.A., Rome, Italy, an affiliate of Merck KGaA","award":["10.13039\/100009945"],"award-info":[{"award-number":["10.13039\/100009945"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Multiple sclerosis (MS) is an autoimmune condition characterized by inflammatory demyelination that leads to irreversible neurological damage within the central nervous system (CNS). This review examines the therapeutic potential and clinical efficacy of cladribine tablets (CladT) for treating MS, focusing on the immune reconstitution mechanism and CNS effects. CladT represents a notable advance among disease-modifying therapies for MS due to its selective targeting of lymphocytes, resulting in sustained yet reversible immune modulation. This action leads to a substantial reduction in memory B cells while preserving the innate immune system and maintaining immunoglobulin levels, thereby mitigating the risks of secondary autoimmunity and infection. Cladribine appears to penetrate the blood\u2013brain barrier, as indicated by cerebrospinal fluid (CSF) studies from parenteral cladribine use. In MS, CladT is associated with reductions in CSF immunological markers, such as oligoclonal bands and neurofilament light chain levels; it also mitigates acute and chronic inflammation, as evidenced, respectively, by consistent reductions in unique active lesions, and significant decrease in slowly expanding lesions in patients with predominant grey matter damage. These findings underscore the potential of CladT in reducing disability accumulation and improving long-term clinical outcomes in patients with highly active disease. By synthesizing data from clinical trials and real-world studies, this review underscores the effectiveness of CladT in reducing relapse rates, disability progression and magnetic resonance imaging-detected disease activity and emphasizes the importance of early high-efficacy treatment for optimizing long-term outcomes. Furthermore, emerging biomarkers are discussed as potential tools for predicting individual responses to therapy, thereby enabling more personalized treatment strategies. This review also provides valuable insights into the positive impact of CladT on quality of life measures, long-term outcomes and safety profile, all of which support the use of CladT in the evolving landscape of MS management.<\/jats:p>","DOI":"10.1177\/17562864251342855","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T03:09:28Z","timestamp":1750820968000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Cladribine tablets in the new multiple sclerosis era"],"prefix":"10.1177","volume":"18","author":[{"given":"Fabio","family":"Buttari","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy"},{"name":"Unit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Dolcetti","sequence":"additional","affiliation":[{"name":"Unit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Pozzilli, Italy"},{"name":"Ph.D. Program in Neuroscience, Department of System Medicine, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-5135","authenticated-orcid":false,"given":"Francesca Romana","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Merck Serono S.p.A., an Affiliate of Merck KGaA, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Rizzi","sequence":"additional","affiliation":[{"name":"Merck Serono S.p.A., an Affiliate of Merck KGaA, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Lauritano","sequence":"additional","affiliation":[{"name":"Unit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Borrelli","sequence":"additional","affiliation":[{"name":"Unit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Pozzilli, Italy"},{"name":"Ph.D. Program in Neuroscience, Department of System Medicine, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Azzolini","sequence":"additional","affiliation":[{"name":"Unit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[{"name":"Unit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Assogna","sequence":"additional","affiliation":[{"name":"Merck Serono S.p.A., an Affiliate of Merck KGaA, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Conte","sequence":"additional","affiliation":[{"name":"Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy"},{"name":"Department of Neurology and Clinical Neurophysiology, Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-8545","authenticated-orcid":false,"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome 00133, Italy"},{"name":"Unit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines7010014"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/62.7.723"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh641"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100648"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp070"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.26858"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30959-X"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001718"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000382130"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24747"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq118"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.187"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.110"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e32832b4c76"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00760"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0832"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03116"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1517-1"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000477"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wco.0000245364.51823.3b"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.4.907"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19042203"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000561"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0268-z"},{"key":"e_1_3_5_28_2","unstructured":"Merck Serono Ltd. MAVENCLAD 10\u2009mg tablets summary of product characteristics https:\/\/www.medicines.org.uk\/emc\/product\/8435 (2021 accessed 9 April 2024)."},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0573-4"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231183221"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2106783"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00394-0"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1792885"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105704"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105837"},{"key":"e_1_3_5_36_2","volume-title":"Reasons for and safety of treatment continuation with cladribine tablets (CladT) in year 5 \u2013 first interim analysis of the CLIP-5 study","author":"Korsukewitz C","year":"2024","unstructured":"Korsukewitz C, Richter N, Klehmet J, et al. Reasons for and safety of treatment continuation with cladribine tablets (CladT) in year 5 \u2013 first interim analysis of the CLIP-5 study. In: ECTRIMS Conference 2024, ePoster 1761\/845, 18\u201320 September 2024, Copenaghen."},{"key":"e_1_3_5_37_2","volume-title":"Experience with cladribine tablets beyond year 4: the challenge of the long-term management","author":"Moral AT","year":"2023","unstructured":"Moral AT, Eichau S, Garcia-Soto JD, et al. Experience with cladribine tablets beyond year 4: the challenge of the long-term management. Abstract Number: 1417\/P697. MSMilan 2023, 9th Joint ECTRIMS-ACTRIMS Meeting, October 11\u201313, 2023, Milan."},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106398"},{"key":"e_1_3_5_39_2","unstructured":"EMA. Summary of Product Caractheristics. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lemtrada (accessed 4 April 2024)."},{"key":"e_1_3_5_40_2","unstructured":"EMA. Summary of Product Caractheristics https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/103948s5184lbl.pdf (accessed 31 March 2025)."},{"key":"e_1_3_5_41_2","unstructured":"FDA. Summary of Product Caractheristics https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-warns-about-rare-serious-risks-stroke-and-blood-vessel-wall-tears-multiple-sclerosis-drug (accessed 31 March 2025)."},{"key":"e_1_3_5_42_2","first-page":"35","article-title":"Cladribine tablets\u2019 potential role as a key example of selective immune reconstitution therapy in multiple sclerosis","volume":"8","author":"Boyko AN","year":"2018","unstructured":"Boyko AN, Boyko OV. Cladribine tablets\u2019 potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degener Neurol Neuromuscul Dis 2018; 8: 35\u201344.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00339-7"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30169-6"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.81"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307721"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2021.06.007"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123070"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105311"},{"key":"e_1_3_5_50_2","volume-title":"(DMT01) Effect of Cladribine tablets on markers of disease progression, axonal loss, and oligoclonal bands in patients with relapsing multiple sclerosis: results from MAGNIFY-MS","author":"De Stefano N","year":"2024","unstructured":"De Stefano N, Achiron A, Barkhof F, et al. (DMT01) Effect of Cladribine tablets on markers of disease progression, axonal loss, and oligoclonal bands in patients with relapsing multiple sclerosis: results from MAGNIFY-MS. In: Abstracts from the 38th Annual Meeting of the Consortium of Multiple Sclerosis Centers, poster no. DMT01, 29 May\u20131 June 2024, Nashville, Tennessee."},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104322"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01074-3"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001187"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70023-0"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70005-5"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104491"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578164"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e318204cd90"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200048"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.119"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000360"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.038"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419854986"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107885"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11700-7"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104735"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00364-6"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103755"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577966"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420922685"},{"key":"e_1_3_5_73_2","article-title":"The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study","volume":"3","author":"Freedman MS","year":"2017","unstructured":"Freedman MS, Leist TP, Comi G, et al. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study. Mult Scler J Exp Transl Clin 2017; 3: 2055217317732802.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2011.08.006"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231205962"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389557519666191015201755"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102962"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211012835"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221099413"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.1.143.143"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.11.6865"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.12.5677"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92826-2"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X233142"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.5.1145"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.4.1716"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-246140"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317411"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.11.027"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129182"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.090340"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci3031282"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42570-2"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a029025"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00498-5"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25927"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.08.011"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.10.001"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103931"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51206"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.02.018"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8830-y"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103431"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.01.042"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676686"},{"key":"e_1_3_5_106_2","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03364036?rank=1 (accessed 31 March 2025)."},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202961"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03040-8"},{"key":"e_1_3_5_109_2","article-title":"The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis","volume":"9","author":"Lycett MJ","year":"2023","unstructured":"Lycett MJ, Lea RA, Maltby VE, et al. The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis. Mult Scler J Exp Transl Clin 2023; 9: 20552173221149688.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_5_110_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457465"},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.09.001"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12121595"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0676"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810262"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26684"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110304"},{"key":"e_1_3_5_117_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13473"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076487"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343892"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732020-00003"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0695-9"},{"key":"e_1_3_5_122_2","first-page":"1235","article-title":"Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia","volume":"54","author":"Kearns CM","year":"1994","unstructured":"Kearns CM, Blakley RL, Santana VM, et al. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res 1994; 54: 1235\u20131239.","journal-title":"Cancer Res"},{"key":"e_1_3_5_123_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20890"},{"key":"e_1_3_5_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.10.006"},{"key":"e_1_3_5_125_2","volume-title":"Effect of cladribine tablets on markers of disease progression, axonal loss, and oligoclonal bands in patients with relapsing multiple sclerosis: results from MAGNIFY-MS","author":"De Stefano N","year":"2024","unstructured":"De Stefano N, Achiron A, Barkhof F. Effect of cladribine tablets on markers of disease progression, axonal loss, and oligoclonal bands in patients with relapsing multiple sclerosis: results from MAGNIFY-MS. In: Abstracts from the 38th Annual Meeting of the Consortium of Multiple Sclerosis Centers, Poster no. DMT01, 29 May\u20131 June 2024, Nashville, Tennessee."},{"key":"e_1_3_5_126_2","unstructured":"Wiendl H Derfuss T Schmierer K et al. O037\/579. Evaluation of the treatment response to cladribine tablets using a transcriptomics and proteomics approach in the cerebrospinal fluid and peripheral blood of people with multiple sclerosis. Mult Scler J 2024; 30(Suppl. 3). https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/13524585241269218 (accessed 27 November 2024)."},{"key":"e_1_3_5_127_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044067"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009097"},{"key":"e_1_3_5_129_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252313153"},{"key":"e_1_3_5_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105701"},{"key":"e_1_3_5_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104662"},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2013.08.009"},{"key":"e_1_3_5_133_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22512"},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512440207"},{"key":"e_1_3_5_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108571"},{"key":"e_1_3_5_136_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211049392"},{"key":"e_1_3_5_137_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211010294"},{"key":"e_1_3_5_138_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231161494"},{"key":"e_1_3_5_139_2","volume-title":"Long-term effectiveness of cladribine tablets over 4\u2009years in relapsing multiple sclerosis: results from the MAGNIFY-MS extension study","author":"De Stefano N","year":"2024","unstructured":"De Stefano N, Vermersch P, Wiendl H, et al. Long-term effectiveness of cladribine tablets over 4\u2009years in relapsing multiple sclerosis: results from the MAGNIFY-MS extension study. In: ECTRIMS 2024, Poster no. P349\/560, 18\u201324 September 2024, Copenaghen, Denmark."},{"key":"e_1_3_5_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106121"},{"key":"e_1_3_5_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.021"},{"key":"e_1_3_5_142_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000158"},{"key":"e_1_3_5_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102572"},{"key":"e_1_3_5_144_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211012227"},{"key":"e_1_3_5_145_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X21666230322140711"},{"key":"e_1_3_5_146_2","volume-title":"ACTRIMS 2025","author":"Leist T","unstructured":"Leist T, et al Safety of cladribine tablets in the treatment of people with multiple sclerosis: 2024 post-approval update with a focus on infection risk. In: ACTRIMS 2025, P400, 27 February\u20131 March 2025, West Palm Beach, FL, USA."},{"key":"e_1_3_5_147_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000552"},{"key":"e_1_3_5_148_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520921087"},{"key":"e_1_3_5_149_2","article-title":"Effectiveness of cladribine in multiple sclerosis \u2013 clinical experience of two tertiary centers","author":"Barros A","year":"2020","unstructured":"Barros A, Santos M, Sequeira J, et al. Effectiveness of cladribine in multiple sclerosis \u2013 clinical experience of two tertiary centers. Mult Scler J 2020; 26(Suppl. 3): 278\u2013278.","journal-title":"Mult Scler J"},{"key":"e_1_3_5_150_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00489"},{"key":"e_1_3_5_151_2","first-page":"305","article-title":"Safety and tolerability of cladribine in multiple sclerosis \u2013 clinical experience of two tertiary centers","author":"Santos M","year":"2020","unstructured":"Santos M, Barros A, Sequeira J, et al. Safety and tolerability of cladribine in multiple sclerosis \u2013 clinical experience of two tertiary centers. Mult Scler J 2020; 305\u2013306.","journal-title":"Mult Scler J"},{"key":"e_1_3_5_152_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000598"},{"key":"e_1_3_5_153_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16250"},{"key":"e_1_3_5_154_2","article-title":"Cladribine tablets in highly-active relapsing multiple sclerosis real-world effectiveness in UK clinical practice (CAMELOT-MS)","volume":"95","author":"Wallace B","year":"2024","unstructured":"Wallace B, David R, Niall M, et al. Cladribine tablets in highly-active relapsing multiple sclerosis real-world effectiveness in UK clinical practice (CAMELOT-MS). J Neurol Neurosurg Psychiatry 2024; 95: A43.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_5_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102929"},{"key":"e_1_3_5_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102452"},{"key":"e_1_3_5_157_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05409-6"},{"key":"e_1_3_5_158_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103150"},{"key":"e_1_3_5_159_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2024.108615"},{"key":"e_1_3_5_160_2","article-title":"Family planning in fertile-age patients with multiple sclerosis (MS) (ConPlanEM Study): Delphi consensus statements","volume":"15","author":"Oreja-Guevara C","year":"2023","unstructured":"Oreja-Guevara C, Tintor\u00e9 M, Meca V, et al. Family planning in fertile-age patients with multiple sclerosis (MS) (ConPlanEM Study): Delphi consensus statements. Cureus 2023; 15: e44056.","journal-title":"Cureus"},{"key":"e_1_3_5_161_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00948-x"},{"key":"e_1_3_5_162_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221131486"},{"key":"e_1_3_5_163_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12291-7"},{"key":"e_1_3_5_164_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517690269"},{"key":"e_1_3_5_165_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15579"},{"key":"e_1_3_5_166_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251313749"},{"key":"e_1_3_5_167_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24954"},{"key":"e_1_3_5_168_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy154"},{"key":"e_1_3_5_169_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007032"},{"key":"e_1_3_5_170_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab241"},{"key":"e_1_3_5_171_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00427-8"},{"key":"e_1_3_5_172_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202728"},{"key":"e_1_3_5_173_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001139"},{"key":"e_1_3_5_174_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2022.103048"},{"key":"e_1_3_5_175_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00654-5"},{"key":"e_1_3_5_176_2","volume-title":"Cladribine tablets reduce slowly expanding lesions in gray matter-driven MRI phenotype and active lesions in all sustain-based MRI phenotypes of MS patients","author":"De Stefano N","year":"2024","unstructured":"De Stefano N, Gentile G, Cacciante F, et al. Cladribine tablets reduce slowly expanding lesions in gray matter-driven MRI phenotype and active lesions in all sustain-based MRI phenotypes of MS patients. In: ECTRIMS 2024, Poster no. P207\/1740, 18\u201324 September 2024, Copenaghen, Denmark."},{"key":"e_1_3_5_177_2","volume-title":"Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study","author":"Selmaj K","year":"2024","unstructured":"Selmaj K, Langdon D, Brochet B, et al. Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study. In: ECTRIMS 2024, Poster no. P846\/1650, 18\u201324 September 2024, Copenaghen, Denmark."},{"key":"e_1_3_5_178_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101944"},{"key":"e_1_3_5_179_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517726380"},{"key":"e_1_3_5_180_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1422078"},{"key":"e_1_3_5_181_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.1362"},{"key":"e_1_3_5_182_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0412-5"},{"key":"e_1_3_5_183_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000289"},{"key":"e_1_3_5_184_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02682-z"},{"key":"e_1_3_5_185_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106272"},{"key":"e_1_3_5_186_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06197-3"},{"key":"e_1_3_5_187_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12389-y"},{"key":"e_1_3_5_188_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200167"},{"key":"e_1_3_5_189_2","first-page":"410","article-title":"Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis","volume":"95","author":"Fissolo N","year":"2024","unstructured":"Fissolo N, Benkert P, Sastre-Garriga J, et al. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2024; 95: 410\u2013418.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_5_190_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23115877"},{"key":"e_1_3_5_191_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1233546"},{"key":"e_1_3_5_192_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvp151"},{"key":"e_1_3_5_193_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.700385"},{"key":"e_1_3_5_194_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702228104"},{"key":"e_1_3_5_195_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2011.00540.x"},{"key":"e_1_3_5_196_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4250480"},{"key":"e_1_3_5_197_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2019.101664"},{"key":"e_1_3_5_198_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2018.01.005"},{"key":"e_1_3_5_199_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14301-3"},{"key":"e_1_3_5_200_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2877728"},{"key":"e_1_3_5_201_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234869"},{"key":"e_1_3_5_202_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2018.03.035"},{"key":"e_1_3_5_203_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2536-13.2013"},{"key":"e_1_3_5_204_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107522"},{"key":"e_1_3_5_205_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab059"},{"key":"e_1_3_5_206_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101280"},{"key":"e_1_3_5_207_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes11101152"},{"key":"e_1_3_5_208_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903071038"},{"key":"e_1_3_5_209_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104459"},{"key":"e_1_3_5_210_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00422-z"},{"key":"e_1_3_5_211_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11111519"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251342855","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251342855","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251342855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:06:14Z","timestamp":1767675974000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251342855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":210,"alternative-id":["10.1177\/17562864251342855"],"URL":"https:\/\/doi.org\/10.1177\/17562864251342855","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"article-number":"17562864251342855"}}